Long‐term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane

INTRODUCTION: The prognosis of patients with unresectable adrenocortical carcinoma is poor. Mitotane is the first‐line treatment for this disease, and etoposide/doxorubicin/cisplatin/mitotane therapy is recommended as first‐line chemotherapy in unresponsive cases. We present a case of long‐term survival following combination chemotherapy with paclitaxel and carboplatin plus mitotane to manage mitotane‐refractory advanced adrenocortical carcinoma. CASE PRESENTATION: A 49‐year‐old woman with a left adrenal tumor, lymph node metastasis around the aorta, and multiple liver metastases was treated with mitotane. The disease progressed despite mitotane therapy; thus, combination chemotherapy with paclitaxel and carboplatin plus mitotane was administered for 9 months. Primary adrenal resection was performed after the liver metastasis had completely dissapeared. She has remained alive for 20 years since her initial diagnosis while undergoing mitotane therapy. CONCLUSION: In this case, combination chemotherapy with paclitaxel and carboplatin plus mitotane effectively controlled advanced adrenocortical carcinoma.